Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A Bayle; F Peyraud; L Belcaid; M Brunet; M Aldea; R Clodion; P Dubos; D Vasseur; C Nicotra; A Geraud; M Sakkal; L Cerbone; F Blanc-Durand; F Mosele; P Martin Romano; M Ngo Camus; I Soubeyran; E Khalifa; M Alame; L Blouin; D Dinart; C Bellera; A Hollebecque; S Ponce; Y Loriot; B Besse; L Lacroix; E Rouleau; F Barlesi; F Andre; A Italiano

doi:10.1016/j.annonc.2022.08.089

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

Ann Oncol. 2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089. Epub 2022 Sep 17.

Authors

A Bayle¹, F Peyraud², L Belcaid³, M Brunet⁴, M Aldea⁵, R Clodion⁶, P Dubos⁴, D Vasseur⁷, C Nicotra⁶, A Geraud⁶, M Sakkal⁶, L Cerbone⁸, F Blanc-Durand⁸, F Mosele⁸, P Martin Romano⁶, M Ngo Camus⁶, I Soubeyran⁹, E Khalifa⁹, M Alame⁹, L Blouin⁹, D Dinart¹⁰, C Bellera¹⁰, A Hollebecque⁶, S Ponce⁶, Y Loriot⁶, B Besse⁵, L Lacroix⁷, E Rouleau⁷, F Barlesi¹¹, F Andre⁵, A Italiano¹²

Affiliations

¹ Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif.
² Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux; University of Bordeaux, Bordeaux, France.
³ Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Oncology, Rigshospitalet, The University of Copenhagen, Copenhagen, Denmark.
⁴ Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
⁵ Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
⁶ Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
⁷ Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
⁸ Department of Cancer Medicine, Gustave Roussy, Villejuif.
⁹ Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
¹⁰ University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, Bordeaux; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux.
¹¹ Department of Cancer Medicine, Gustave Roussy, Villejuif; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
¹² Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux; University of Bordeaux, Bordeaux, France. Electronic address: Antoine.italiano@gustaveroussy.fr.

PMID: 36122799
DOI: 10.1016/j.annonc.2022.08.089

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Liquid Biopsy
Neoplasms* / diagnosis
Neoplasms* / drug therapy
Precision Medicine*